Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Pulmonary fibrosis HP Pulmonary fibrosis MESHD and its related factors in discharged patients with new coronavirus pneumonia MESHD pneumonia HP: A cohort study of 90-150 days follow-up after onset

    Authors: Xiaohe Li; Chenguang Shen; Lifei Wang; Sumit Majumder; Die Zhang; M. Jamal Deen; Yanjie Li; Ling Qing; Ying Zhang; Chuming Chen; Rongrong Zou; Jianfeng Lan; Ling Huang; Cheng Peng; Lijiao Zeng; Yanhua Liang; Mengli Cao; Yang Yang; Minghui Yang; Guoyu Tan; Shenghong Tang; Lei Liu; Jing Yuan; Yingxia Liu

    doi:10.21203/rs.3.rs-79977/v1 Date: 2020-09-18 Source: ResearchSquare

    Background: Thousands of the Coronavirus Disease MESHD 2019 (COVID-19) patients have been discharged from hospitals, long-term follow-up studies are required to evaluate the prevalence SERO of post-COVID-19 fibrosis MESHD.Methods: This study involves 462 laboratory confirmed patients with COVID-19 who were admitted to Shenzhen Third People’s Hospital from January 11, 2020 to April 26, 2020. A total of 457 patients underwent thin-section chest CT scans during the hospitalization or after discharge to identify the pulmonary lesion MESHD. A total of 289 patients were followed up from 90 days to 150 days after the onset of the disease.Results:  Parenchymal bands, irregular interfaces, meshwork and traction bronchiectasis HP were the most common CT features in all COVID-19 patients. 86.87%, 74.40%, 79.56%, 68.12% and 62.03% patients developed with pulmonary fibrosis HP pulmonary fibrosis MESHD and 4.53%, 19.61%, 18.02%, 38.30% and 48.98% patients reversed pulmonary fibrosis HP pulmonary fibrosis MESHD during the 0-30, 31-60, 61-90, 91-120 and >120 days after onset, respectively. It was observed that Age TRANS, BMI, Fever HP Fever MESHD, and Highest PCT were predictive factors for sustaining fibrosis MESHD even after 90 days from onset. A predictive model of the persistence with pulmonary fibrosis HP pulmonary fibrosis MESHD was developed based-on the Logistic Regression method with an accuracy, PPV, NPV, Sensitivity SERO and Specificity of the model of 76%, 71%, 79%, 67%, and 82%, respectively. Only a fraction of COVID-19 patients suffered with abnormal lung function MESHD after 90 days from onset, and the ratio of abnormal lung function did not differ on a statistically significant level between the fibrotic and non-fibrotic groups.Conclusions: Long-term pulmonary fibrosis HP pulmonary fibrosis MESHD was more likely to develop in patients with older age TRANS, high BMI, severe/critical condition, fever HP fever MESHD, long time to turn the viral RNA negative, pre-existing disease and delay to admission. Fibrosis MESHD developed in COVID-19 patients could be reversed in about a half of the patients after 120 days from onset. The pulmonary function of most of COVID-19 patients with pulmonary fibrosis HP pulmonary fibrosis MESHD could turn to normal condition after three months from onset. An effective prediction model with an average Area Under the Curve (AUC) of 0.84 was established to predict the persistence of pulmonary fibrosis HP pulmonary fibrosis MESHD in COVID-19 patients for early diagnosis.

    Vitamin D deficiency in critically ill MESHD patients diagnosed with COVID -19. Are we doing enough? A retrospective analysis of 226 patients.

    Authors: Tomás Cuñat; Antonio Ojeda; Andrea Calvo

    doi:10.21203/rs.3.rs-30390/v1 Date: 2020-05-19 Source: ResearchSquare

    Vitamin D deficiency MESHD is common in critically ill patients, and its role in COVID-19 patients could be important. Its deficiency has been associated with respiratory distress HP respiratory distress MESHD syndrome, pulmonary fibrosis HP pulmonary fibrosis MESHD (through activation of the renin-angiotensin system), increased levels of IL-2, and cardiovascular adverse events. Various scientific societies recommend the screening of vitamin D in individuals at risk for deficiency. Despite that, the demographics of Vitamin D levels amongst critically ill patients with a confirmed diagnosis of COVID-19 are currently unknown. We propose a study to determine the prevalence SERO of vitamin D deficiency MESHD in a consecutive population of COVID-19 patients admitted to intensive care units and to evaluate its relationship with clinical outcomes. We study 226 COVID-19 patients between March 16 and April 26, 2020. The prevalence SERO of vitamin D deficiency could not be determined because the value of 25-hydroxyvitamin D was obtained in a few patients (17 patients, 7,5%). However, all patients with serum SERO determinations of 25-hydroxyvitamin D presented a level lower than 20 ng/ml and thirteen patients (76,5%) levels < 12,5 ng/ml. We conclude that undiagnosed vitamin D deficiency MESHD is common in critically ill COVID-19 patients, and physicians should be conscious of the relevance of its monitoring and supplementation.

    Identification of pulmonary comorbid diseases network based repurposing effective drugs for COVID-19

    Authors: Jai Chand Patel; Rajkumar Tulswani; Pankaj Khurana; Yogendra Kumar Sharma; Lilly Ganju; Bhuvnesh Kumar; Ragumani Sugadev

    doi:10.21203/rs.3.rs-28148/v1 Date: 2020-05-08 Source: ResearchSquare

    The number of hospitalization of COVID-19 patients with one or more comorbid diseases is highly alarming. Despite the lack of large clinical data and incomplete understanding of virus pathology, identification of the COVID-19 associated diseases with clinical precision are highly limited. In this regard, our text mining of 6238 PubMed abstracts (as on 23 April 2020) successfully identified broad spectrum of COVID-19 comorbid diseases/disorders (54), and their prevalence SERO on the basis of the number of occurrence of disease terms in the abstracts. The disease ontology based semantic similarity network analysis revealed the six highly comorbid diseases of COVID-19 namely Viral Pneumonia HP, Pulmonary Fibrosis HP Pulmonary Fibrosis MESHD, Pulmonary Edema HP Pulmonary Edema MESHD, Acute Respiratory Distress Syndrome MESHD Respiratory Distress HP Syndrome ( ARDS MESHD), Chronic Obstructive Pulmonary Disease HP Chronic Obstructive Pulmonary Disease MESHD ( COPD MESHD) and Asthma HP. The disease gene bipartite network revealed 15 genes that were strongly associated with several viral pathways including the corona viruses may involve in the manifestation (mild to critical) of COVID-19. Our tripartite network- based repurposing of the approved drugs in the world market revealed six promising drugs namely resveratrol, dexamethasone, acetyl cysteine, Tretinoin, simvastatin and aspirin to treat comorbid symptoms of COVID-19 patients. Our animal studies in rats and literatures strongly supported that resveratrol is the most promising drug to possibly reduce several comorbid symptoms associated with COVID-19 including the severe hypoxemia HP hypoxemia MESHD induced vascular leakage. Overall, the anti-viral properties of resveratrol against corona virus could be readily exploited to effectively control the viral load at early stage of COVID-19 infection through nasal administration.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.